Manuel Mateo P. E.
- Country
- Spain
- Department
- 3207: Hematologia
Research Overview
- A Phase 1/2 Study of Enzomenib (DSP 5336) in Adults with Relapsed or Refractory Acute Leukemia, Including MLL-Rearranged or NPM1-Mutated Subtypes
- Phase 2 Study of Iadademstat in Patients with Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
- Long-term Safety of Asciminib in Patients With Philadelphia Chromosome-Positive CML or ALL Continuing From Parent Studies
Data & Insights
Has run more than one trial at 131 of 281 partner sites.
Specializations
Myeloproliferative Disorders
The investigator specializes in treating myeloproliferative neoplasms, with particular expertise in myelofibrosis and essential thrombocythemia. Their research encompasses innovative therapeutic approaches for patients with anemia complications and those who show inadequate response to conventional treatments.
- JAK2 inhibitor therapy optimization
- Transfusion-dependent myelofibrosis
- Treatment-resistant essential thrombocythemia
Leukemia Management
The investigator focuses on advancing treatment options for various forms of leukemia, particularly chronic myeloid leukemia and acute myeloid leukemia. Their work includes evaluation of novel therapeutic agents and combination strategies.
- BCR-ABL1+ CML treatment optimization
- FLT3-ITD negative AML therapies
- TKI-resistant chronic phase CML
Lymphoma Research
The investigator has significant expertise in treating classical Hodgkin lymphoma, with a focus on developing frontline therapeutic strategies for advanced disease stages. Their research evaluates novel therapeutic combinations to improve treatment outcomes.
- Advanced Hodgkin lymphoma therapy
- Targeted antibody-drug conjugates
- Combined modality treatment approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.